The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and manufacturers.

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate,